Eesti - eesti - Ravimiamet

aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 30mg 30tk; 30mg 100tk; 30mg 250tk; 30mg 14tk; 30mg 50tk; 30mg 28tk; 30mg 10tk; 30mg 20tk; 30mg 98tk; 30mg 56tk

Eesti - eesti - Ravimiamet

glaxosmithkline (ireland) limited - paroksetiin - õhukese polümeerikattega tablett - 20mg 100tk; 20mg 30tk

Eesti - eesti - Ravimiamet

gedeon richter plc. - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Eesti - eesti - Ravimiamet

ideal trade links uab - paroksetiin - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 30tk; 20mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosupressandid - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosupressandid - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosuppressants, valikuline immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 28tk